Start for free
Start for free
FC Capital logo

FC Capital

Asia, Shanghai, China, Shanghai

Description

Fengchuan Capital is a private equity investment firm focused on the complete medical and pharmaceutical industry chain.

Investor Profile

FC Capital has made 6 investments, with 1 in the past 12 months and 33% as lead.

Stage Focus

  • Series A (67%)
  • Series C (17%)
  • Series B (17%)

Country Focus

  • United States (33%)
  • China (33%)
  • Switzerland (33%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Biopharma
  • Oncology
  • Pharmaceutical
  • Therapeutics
  • Business Development
  • Clinical Trials
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does FC Capital frequently co-invest with?

Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
North America, New York, United States, New York
Co-Investments: 1
Shinhan Private Equity
Shinhan Private Equity
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
Bristol-Myers Squibb
Bristol-Myers Squibb
North America, New York, United States, New York
Co-Investments: 1
Shinhan Capital
Shinhan Capital
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
SV Investment Corp
SV Investment Corp
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
Cathay Capital
Cathay Capital
Europe, Ile-de-France, France, Paris
Co-Investments: 1
QUAD Investment Management
QUAD Investment Management
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
Partners Investment
Partners Investment
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 2
RC
Rockspring Capital
North America, Texas, United States, Houston
Co-Investments: 1
PPF Group
PPF Group
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 2

What are some of recent deals done by FC Capital?

iRegene

Wuhan, Hubei, China

iRegene researches and develops pharmaceutical therapy for neurodegenerative and rare diseases.

Health CareMedicalTherapeutics
Series BApr 11, 2025
Amount Raised: $13,654,114
Degron Therapeutics

Shanghai, Shanghai, China

Degron Therapeutics is a platform company in discovery of molecular glue degraders for cancer treatment.

BiotechnologyHealth CareOncology
Series AJan 22, 2025
Lupeng Pharmaceutical

Guangzhou, Guangdong, China

Lupeng Pharmaceutical is a biotech company that focuses on the drug discovery and development of novel therapies for cancer treatment.

BiotechnologyHealth CareMedicalOncologyPharmaceutical
Series ANov 14, 2022
Amount Raised: $35,000,000
Harvest Integrated Research Organization

Excelsior, Minnesota, United States

Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO).

BiopharmaBiotechnologyClinical TrialsMedicalPharmaceutical
Series AMar 18, 2022
Amount Raised: $1,572,030
Cellestia

Basel, Basel-Stadt, Switzerland

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.

BiopharmaBiotechnologyHealth CareTherapeutics
Series BDec 17, 2019
Amount Raised: $20,408,705
Vedanta Biosciences

Cambridge, Massachusetts, United States

Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.

BiotechnologyBusiness DevelopmentMedical
Series CSep 23, 2019
Amount Raised: $16,600,000
Cellestia

Basel, Basel-Stadt, Switzerland

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.

BiopharmaBiotechnologyHealth CareTherapeutics
Series ADec 19, 2018
Amount Raised: $20,120,502
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsNewsletterPricing

Free tools

Pre-Money and Post-Money Valuation Calculator